Cheplapharm Arzneimittel
As of the edition of 20 October 2026, Cheplapharm Arzneimittel runs 30 drugs, 30 of them marketed; it is on route A at 0 targets and on route B at 15 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 30 |
| Total | 30 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Dexamethasone | none listed | 5 |
| Doxorubicin | none listed | 3 |
| Capecitabine | none listed | 1 |
| Metformin | none listed | 4 |
| Etoposide | none listed | 5 |
| Budesonide | Ends 2029 (exclusivity) | 5 |
| Pioglitazone | none listed | 2 |
| Omeprazole | none listed | 2 |
| Quetiapine | none listed | 4 |
| Hydrochlorothiazide | none listed | 4 |
| Hydroxyurea | none listed | 1 |
| Tretinoin | none listed | 3 |
| Amphotericin b | none listed | 0 |
| Glimepiride | none listed | 3 |
| Ganciclovir | none listed | 0 |
| Etoposide phosphate | none listed | 2 |
| Valganciclovir | none listed | 0 |
| Candesartan cilexetil | none listed | 2 |
| Colesevelam | none listed | 0 |
| Orlistat | none listed | 2 |
| Verteporfin | none listed | 0 |
| Neomycin | none listed | 0 |
| Alfacalcidol | none listed | 0 |
| Clonazepam | none listed | 0 |
| Buserelin | none listed | 1 |
A route B row is one company at one target. 5 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 0 targets, route B at 15 targets.
All 15 rows on route A or B
In the product15 company-target rows on route A or B; 12 are not shown here, and no score is.
See all 15 targets where Cheplapharm Arzneimittel needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.